Two Medication Classes Demonstrate Promise in Preventing Cardiovascular and Liver Complications in Individuals with Type 2 Diabetes
New research indicates that two distinct medication classes, Sodium-Glucose Co-Transporters 2 (SGLT2) inhibitors and Glucagon-Like Peptide-1 (GLP-1) receptor agonists, significantly decrease the risk of cardiovascular …